Momenta Pharmaceuticals Announces Appointment of James R. Sulat to Board of Directors
Posted on: Wednesday, 11 June 2008, 09:01 CDT
CAMBRIDGE, Mass., June 11, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of James R. Sulat, Chief Financial Officer and Director of Memory Pharmaceuticals Corp., to its Board of Directors effective June 5, 2008.
James R. Sulat has served as the Chief Financial Officer of Memory Pharmaceuticals since February 2008 and previously served as Memory Pharmaceuticals' President and Chief Executive Officer from May 2005 until February 2008. Jim has also served as a member of the board of directors of Memory Pharmaceuticals since May 2005. From May 2003 to February 2004, Mr. Sulat served as the Senior Executive Vice President of Moore Wallace Incorporated. Following the acquisition of Moore Wallace by R.R. Donnelley & Sons Company in February 2004, Mr. Sulat became Chief Financial Officer of R.R. Donnelley and served in that position until May 2004. From 1998 to 2003, Mr. Sulat served as Vice President and Chief Financial Officer of Chiron Corporation. Mr. Sulat serves as a director of Maxygen, Inc. and Intercell AG.
"We are very pleased that Jim has joined our Board of Directors. Jim brings extensive expertise in finance and general management as well as board experience. His strategic insights in both large and small biotechnology companies will be invaluable as we grow our organization," stated Craig Wheeler, President and Chief Executive Officer of Momenta.
"I am delighted to be joining the board of Momenta at such an exciting time for the company, as M-Enoxaparin moves forward through the ANDA process, and as the company applies its proprietary technology to complex generics, follow-on biologics and novel drugs," said Mr. Sulat. "I look forward to contributing to these efforts."
Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trade names and service marks are the property of Momenta Pharmaceuticals, Inc. Other trademarks or service marks appearing in this press release are the property of their respective owners and are not the property of Momenta Pharmaceuticals, Inc. or its subsidiaries.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley 617-395-5189
Source: PrimeNewswire
Related Articles
- Xethanol Hires Dr. Rom Papadopoulos As New Chief Operating Officer and Chief Financial Officer
- Momenta Pharmaceuticals to Present At 2008 Citi Investment Research Global Healthcare Conference
- Momenta Pharmaceuticals Appoints Dr. James M. Roach As Chief Medical Officer
- Momenta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2008
- Momenta Pharmaceuticals Announces Appointment of Elizabeth Stoner, M.D. To Board of Directors
- Momenta Pharmaceuticals Initiates Phase 2 Study of Novel Anticoagulant M118
- La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
- Momenta Pharmaceuticals Announces Appointment of Paul D. Goldenheim, M.D. To Board of Directors
- Par Pharmaceutical Names Gerard A. Martino Chief Financial Officer
 |
 |
User Comments (0)
RSS Feeds